1Cudrun HR, Jana OK, Carl TW. High-resolution DNA melting analysis for simple and efficient molecular diagnostics. Pharmacogenomics, 2007, 8:597-608.
2Demorais SMF, Wilkinson GR, Blaisdell J, et al. Identification of a new genetic-defect responsible for the polymorphism of (s)- mephenytoin metabolism in Japanese. Mol Pharmacol, 1994, 46: 594-598.
3Goldstein JA, Blaisdell J. Genetic tests which identify the principal defects in CYP2C19 responsible for the polymorphism in mephenytoin metabolism. Methods Enzymol, 1996, 272: 210- 218.
4Xiao ZS, Goldstein JA, Xie HG, et ah Differences in the incidence of the CYP2C19 polymorphism affecting the S- mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele. J Pharmacol Exp Tiler, 1997, 281 : 604-609.
5Zhou HH. Cyp2c19 genotype determines enzyme activity and inducibility of s-mephenytoin hydroxylase. Clin Chim Acta, 2001, 313 : 203-208.
6Tomalik-Scharte D, Lazar A, Fuhr U, et al. The clinical role of genetic polymorphisms in drug-metabolizing enzymes. Pharmacogenomics J, 2007, 8 : 4-15.
7Hen'mann MG, Durtschi JD, Bromley LK, et al. Amplicon DNA melting analysis for mutation scanning and genotyping: cross- platform comparison of instruments and dyes. Clin Chem, 2006, 52 : 494-503.
